Report Name: Alnylam Pharmaceuticals, Inc. Profile – Overview, History, SWOT Analysis, Products/Services, Facts, Financials, Key Executives, Competitors, Tech Intelligence, IT Outsourcing, IT Management, Recent Developments and Strategy Evaluation
Alnylam Pharmaceuticals, Inc. Report – Publisher: Research Cosmos
Price Scheme of the Report:
Single User License – USD 150
Team License – USD 175
Corporate License – USD 250
Alnylam Pharmaceuticals, Inc. – Business Description:
Alnylam Pharmaceuticals, Inc. is a US-based company engaged in the development and commercialization of novel ribonucleic acid interference (RNAi) therapeutics for the treatment of genetically defined diseases. The company operates in the US, Germany and the UK. The company’s products in clinical or pre-clinical development include ALN-TTR, ALN-AT3, ALN-AS1, ALN-PCS, ALN-ANG, ALN-AGT, ALN-CC5, ALN-AAT, ALN-HBV, ALN-HDV, ALN-TMP and ALN-GO1. Alnylam’s ALN-TTR targets the transthyretin gene for the treatment of TTR-mediated amyloidosis (ATTR), which is an inherited, debilitating and fatal disease caused by a mutation in the TTR gene. The company’s ALN-AT3 is an RNAi therapeutic targeting antithrombin (AT), a genetically defined target, for the treatment of hemophilia, a hereditary disorder caused by deficiencies of blood clotting factors, and (rare bleeding disorders) RBD. Alnylam’s ALN-AS1 is an RNAi therapeutic targeting aminolevulinate synthase 1 (ALAS-1), for the treatment of acute intermittent porphyria, a hepatic porphyria caused by deficiency in the enzyme porphobilinogen deaminase. The cardio-metabolic diseases are treated using the following: ALN-PCS is an RNAi therapeutic, targeting proprotein convertase subtilisin and kexin type 9 (PCSK9) for the treatment of hypercholesterolemia; ALN-ANG is an RNAi therapeutic, targeting the gene angiopoietin-like 3 (ANGPTL3) for the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia; and ALN-AGT is a subcutaneously administered RNAi therapeutic, targeting angiotensinogen (AGT) for the treatment of hypertensive disorders of pregnancy (HDP). The company’s ALN-CC5, an RNAi therapeutic targeting complement component C5, is used in the treatment complement-mediated diseases. The ALN-AAT is a liver-produced serine proteinase inhibitor, targets alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease. Its ALN-HBV is an RNAi therapeutic targeting the hepatitis B virus (HBV) genome for the treatment of HBV infection and ALN-HDV, an RNAi therapeutic, targets the hepatitis delta viral (HDV) genome for the treatment of HDV infection. Alnylam’s other genetic medicines offers ALN-GO1 targeting glycolate oxidase (GO) for the treatment of primary hyperoxaluria type 1 (PH1). The company’s subsidiaries include Alnylam U.S., Inc., Alnylam Europe AG, Alnylam Securities Corporation, Alnylam UK Limited, Sirna Therapeutics and Alnylam (Bermuda) Ltd.
Scope of the Report:
About the Company: Historical Details, Current Ownership Structure and basic overview of Balfour Beatty plcin terms of revenue, net income, and operating income.
Financials: Details about Balfour Beatty plclisting status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.
Products/Services: Listing of the company’s entire portfolio along with the description of individual products/services providing a clear picture of their target audience.
Company SWOT Analysis: Outlines Atea ASA.’s strengths, weaknesses, and opportunities and threats facing the company.
Recent Developments: Showcases Atea ASA.’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.
Strategic Evaluation: This section provides an overview of Atea ASA.’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.
Technology Landscape: Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken by the company at present along with outlook.
Key Questions Answered
What domain does Balfour Beatty plcoperate and what are key points about it?
What is the product/service portfolio of Atea ASA.?
How has Balfour Beatty plcperformed financially from 2013?
How does Balfour Beatty plcrank among its peers in terms of revenue and market share?
What are Balfour Beatty plcstrengths and weaknesses and what opportunities and threats do it face?
What are Atea ASA.’s main growth strategies and how successful has the company been at implementing them?
What is the in-house technical capability of Atea ASA.? Where does it procure/outsource it?
Reasons to buy
Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own
Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at a very competitive cost
12 hour delivery time fulfilling your urgent requests as per your requirement
On-demand customization options that can completely cater to your needs by focusing the report on given specifics
For More Information, Get Sample of the report:Request Sample
Got Some Questions? Inquire Here:Inquire Before Buying
Get This Report:Purchase Now
For More Details, Contact Provider Directly:
+1 888 709 8757